Allarity TherapeuticsALLR
13F holders, Q4 2024 (December 31)6holders +2
3new positions
1sold out
$1.17avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Allarity Therapeutics Inc. (ALLR) in their 13F filings, up 2 from Q3 2024. 3 opened new positions and 1 sold out. The largest holders were Stonepine Capital Management, LLC ($79K), Goldman Sachs Group Inc. ($24K) and Citigroup Inc. ($14K).
- Company
- Allarity Therapeutics Inc.
- CUSIP
- 016744500
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $117K |
| Exits | 1 | $39K |
All 13F filers, Q3 2024 → Q4 2024: 101,073 shares bought and 18,459 shares sold, net +82,614 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Stonepine Capital Management, LLC | 0.06% | New | 67,289 | $79K |
| Goldman Sachs Group Inc. | 0.00% | New | 20,616 | $24K |
| Citigroup Inc. | 0.00% | New | 12,294 | $14K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +25.4% | 4,266 | $5K |
| Bank of America Corp. | 0.00% | Add +100.0% | 22 | $26 |
| Danske Bank A/S | 0.00% | Reduce -87.5% | 1 | $1 |
"% of holder's portfolio" is ALLR's weight in each manager's 13F, not the share of Allarity Therapeutics Inc. the manager owns.